MannKind (MNKD) Posts Q4 Loss of 66c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
MannKind Corporation Reports 2015 Fourth Quarter and Full Year Financial Results
March 14, 2016 4:48 PM EDTVALENCIA, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) (TASE: MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2015.
For the fourth quarter of 2015, research and development expenses decreased 64.8%, from $17.6 million to $6.2 million, reflecting effects of our restructuring measures taken in 2015 and the transition from development to commercial activities. Â General and administrative costs declined 33.6%, from $12.5 million to $8.3 million, mainly due to a decrease in non-cash stock compensation expense. Â Sales of Afrezza continued to be lower than expected during the... More
MannKind Announces Appointment of Michael Castagna as Chief Commercial Officer
March 14, 2016 4:00 PM EDTVALENCIA, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) (TASE: MNKD) today announced that Michael E. Castagna, Pharm.D., has joined the company as its Chief Commercial Officer, effective immediately. Dr. Castagna will lead commercialization efforts for Afrezza®, reporting to Matthew Pfeffer, Chief Executive Officer, and will serve on MannKinds executive leadership team.
Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. Â He joins MannKind from Amgen, Inc., where he spent over three... More
